Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of Option B+ ART in Malawi: few severe maternal toxicity events or infant HIV infections among pregnant women initiating tenofovir/lamivudine/efavirenz.
Harrington BJ, DiPrete BL, Jumbe AN, Ngongondo M, Limarzi L, Wallie SD, Chagomerana MB, Hosseinipour MC; S4 Study Team. Harrington BJ, et al. Among authors: chagomerana mb. Trop Med Int Health. 2019 Oct;24(10):1221-1228. doi: 10.1111/tmi.13296. Epub 2019 Aug 19. Trop Med Int Health. 2019. PMID: 31381233 Free article.
Outcomes and prognostic factors for women with breast cancer in Malawi.
Youngblood VM, Nyirenda R, Nyasosela R, Zuze T, Yang Y, Kudowa E, Moses A, Kincaid J, Kajombo C, Kampani C, Chimzimu F, Mulenga M, Chilima C, Ellis GK, Seguin R, Chagomerana M, Maine R, Jordan S, Charles A, Lee C, Gopal S, Tomoka T. Youngblood VM, et al. Cancer Causes Control. 2020 Apr;31(4):393-402. doi: 10.1007/s10552-020-01282-4. Epub 2020 Mar 2. Cancer Causes Control. 2020. PMID: 32124187 Free PMC article.
Factors associated with a history of treatment interruption among pregnant women living with HIV in Malawi: A cross-sectional study.
Sasse SA, Harrington BJ, DiPrete BL, Chagomerana MB, Klyn LL, Wallie SD, Maliwichi M, Jumbe AN, Hoffman IF, Rosenberg NE, Tang JH, Hosseinipour MC; S4 Study. Sasse SA, et al. Among authors: chagomerana mb. PLoS One. 2022 Apr 19;17(4):e0267085. doi: 10.1371/journal.pone.0267085. eCollection 2022. PLoS One. 2022. PMID: 35439264 Free PMC article.
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
Avihingsanon A, Hughes MD, Salata R, Godfrey C, McCarthy C, Mugyenyi P, Hogg E, Gross R, Cardoso SW, Bukuru A, Makanga M, Badal-Aesen S, Mave V, Ndege BW, Fontain SN, Samaneka W, Secours R, Van Schalkwyk M, Mngqibisa R, Mohapi L, Valencia J, Sugandhavesa P, Montalban E, Munyanga C, Chagomerana M, Santos BR, Kumarasamy N, Kanyama C, Schooley RT, Mellors JW, Wallis CL, Collier AC, Grinsztejn B; A5288 Study team. Avihingsanon A, et al. J Int AIDS Soc. 2022 Jun;25(6):e25905. doi: 10.1002/jia2.25905. J Int AIDS Soc. 2022. PMID: 36039892 Free PMC article.
44 results